Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
about
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?Status of adjuvant endocrine therapy for breast cancer.The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.Do aromatase inhibitors have adverse effects on cognitive function?Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Patterns of change in cognitive function with anastrozole therapy.Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer.Adjuvant ovarian function suppression and cognitive function in women with breast cancer.Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer.Current role and safety profile of aromatase inhibitors in early breast cancer.Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors.Psychosocial care in cancer.Clearing the air: a review of our current understanding of "chemo fog".Safety of aromatase inhibitor therapy in breast cancer.Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?Can Exercise Ameliorate Aromatase Inhibitor-Induced Cognitive Decline in Breast Cancer Patients?The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review.Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy.Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.Assay of Calcium Transients and Synapses in Rat Hippocampal Neurons by Kinetic Image Cytometry and High-Content Analysis: An In Vitro Model System for Postchemotherapy Cognitive Impairment.Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia.Cognitive Effects of Aromatase and Possible Role in Memory Disorders
P2860
Q33729085-8F31B194-9A20-44BF-9A0E-AA59B1CE9CADQ33739138-7E833241-E25A-4E96-BC5B-8A423BBD728BQ33921226-63D2CA09-BF58-4DF6-A955-02E024DDC724Q35029513-48EA82DF-263B-4E22-ACDA-D4EDC54E9D44Q35557992-F22C5A66-8DA4-4982-8205-D80577364C82Q35883135-4C248CE0-8F2A-44D1-8007-348DC617C08EQ35949546-69AA5C79-0578-4DD9-9368-A47802314B3EQ36932994-51B05EDF-8F07-4F4B-813B-05645270F807Q37175081-48B98B17-2695-45F1-84F8-2F54249588D9Q37314706-576C9E4C-8975-4BF7-AA5F-6560A74D4C53Q37931895-F62A5270-E880-40F5-9FE3-45E3AD36DC43Q37931900-A299F7F8-2E66-4D7D-BDBE-E9B3EE6C2723Q37954124-42577C4F-8C27-437A-B2BE-78B0BA0583EEQ38088668-B847E4C3-053A-4260-A8D5-AF1D06ADA70DQ38522924-E5111B40-A3AA-4A6E-A248-A4E3C60A24D7Q38551397-3C446A86-24FF-4C89-B1FE-E8EC5CDB0ACEQ38557077-A80D4E46-84CC-4876-8E89-CB7BAB8763C3Q38653422-CA11FA20-F107-46DC-8CE7-30811E12CBD9Q38786134-84F4A2F2-6554-4281-A56F-75348D5CBAC6Q38901804-3A9955AA-D799-4AA2-AEF5-B2888824B0EDQ45111650-9A9D83E7-4225-48E6-B618-FCAF1E6CB842Q47573348-6128A193-F759-4D49-8D14-359AAF8A684FQ50554157-B2926BF3-6E8A-4AD4-AE9E-268D5D47814BQ50882231-B286386F-0835-4371-A479-01B8EAFF5556Q50914949-74F0E01A-861E-46A5-AFAD-A29BDA0F821BQ58606275-FE8204C4-A5B0-444F-8284-7432B6D6A8A9
P2860
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@ast
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@en
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@nl
type
label
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@ast
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@en
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@nl
prefLabel
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@ast
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@en
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@nl
P2093
P2860
P1476
Cognitive function in postmeno ...... moxifen in the BIG 1-98 trial.
@en
P2093
Alan S Coates
Alastair Thompson
Aron Goldhirsch
Beat Thürlimann
Fatima Cardoso
Julie Aldridge
Jürg Bernhard
Karen N Price
Karin Ribi
Kelly-Anne Phillips
P2860
P2888
P304
P356
10.1007/S10549-010-1235-Y
P407
P577
2010-11-03T00:00:00Z
P5875
P6179
1017835012